 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 December 1999 | Volume 131 Issue 12 | Pages 927-934
Background: Warfarin dramatically reduces the risk for ischemic stroke in nonvalvular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not been widely studied.
Objective: To assess the rates and predictors of warfarin use in ambulatory patients with nonvalvular atrial fibrillation.
Design: Cross-sectional study.
Setting: Large health maintenance organization.
Patients: 13 428 patients with a confirmed ambulatory diagnosis of nonvalvular atrial fibrillation and known warfarin status between 1 July 1996 and 31 December 1997.
Measurements: Data from automated pharmacy, laboratory, and clinical-administrative databases were used to determine the prevalence and determinants of warfarin use in the 3 months before or after the identified diagnosis of atrial fibrillation.
Results: Of 11 082 patients with nonvalvular atrial fibrillation and no known contraindications, 55% received warfarin. Warfarin use was substantially lower in patients who were younger than 55 years of age (44.3%) and those who were 85 years of age or older (35.4%). Only 59.3% of patients with one or more risk factors for stroke and no contraindications were receiving warfarin. Among a subset of "ideal" candidates to receive warfarin (persons 65 to 74 years of age who had no contraindications and had previous stroke, hypertension, or both), 62.1% had evidence of warfarin use. Among our entire cohort, the strongest predictors of receiving warfarin were previous stroke (adjusted odds ratio, 2.55 [95% CI, 2.23 to 2.92]), heart failure (odds ratio, 1.63 [CI, 1.51 to 1.77]), previous intracranial hemorrhage (odds ratio, 0.33 [CI, 0.21 to 0.52]), age 85 years or older (odds ratio, 0.35 [CI, 0.31 to 0.40]), and previous gastrointestinal hemorrhage (odds ratio, 0.47 [CI, 0.40 to 0.57]).
Conclusions: In a large, contemporary cohort of ambulatory patients with atrial fibrillation who received care within a health maintenance organization, warfarin use was considerably higher than in other reported studies. Although the reasons why physicians did not prescribe warfarin could not be elucidated, many apparently eligible patients with atrial fibrillation and at least one additional risk factor for stroke, especially hypertension, did not receive anticoagulation. Interventions are needed to increase the use of warfarin for stroke prevention among appropriate candidates.
Author and Article Information
From Kaiser Permanente Medical Care Program (Northern California), Oakland, and University of California at San Francisco, San Francisco, California; and Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Acknowledgments: The authors thank Vernal Mason and Lori E. Henault for helping to coordinate this project and for technical support.
Grant Support: By Public Health Services research grant AG15478 from the National Institute on Aging.
Requests for Reprints: Alan S. Go, MD, Division of Research, Kaiser Permanente Medical Care Program (Northern California), 3505 Broadway Street, 12th Floor, Oakland, CA 94611-5714; e-mail, axg{at}dor.kaiser.org. For reprint orders in quantities exceeding 100, please contact the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Go and Ms. Phillips: Division of Research, Kaiser Permanente Medical Care Program (Northern California), 3505 Broadway Street, 12th Floor, Oakland, CA 94611-5714.
Drs. Hylek and Singer and Ms. Borowsky: Medical Practices Evaluation Unit, 50 Staniford Street, 9th Floor, Boston, MA 02114.
Dr. Selby: Division of Research, 3505 Broadway Street, 13th Floor, Oakland, CA 94611. ARTICLE
Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. Tang, J. Y. Wan, and J. E. Bailey Performance of Comorbidity Measures to Predict Stroke and Death in a Community-Dwelling, Hypertensive Medicaid Population Stroke, July 1, 2008; 39(7): 1938 - 1944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Douketis, P. B. Berger, A. S. Dunn, A. K. Jaffer, A. C. Spyropoulos, R. C. Becker, and J. Ansell The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 299S - 339S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Fang, A. S. Go, Y. Chang, L. Borowsky, N. K. Pomernacki, D. E. Singer, and for the ATRIA Study Group Comparison of Risk Stratification Schemes to Predict Thromboembolism in People With Nonvalvular Atrial Fibrillation J. Am. Coll. Cardiol., February 26, 2008; 51(8): 810 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation" Circulation, February 5, 2008; 117(5): e150 - e150. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Taggar and G. Y.H. Lip Anticoagulation for elderly patients with atrial fibrillation: not to be neglected Europace, January 1, 2008; 10(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Nutescu ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2281 - 2291. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Connolly, J. Eikelboom, M. O'Donnell, J. Pogue, and S. Yusuf Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation Circulation, July 24, 2007; 116(4): 449 - 455. [Full Text] [PDF]
|
|
|
|
|
|
P. T. Akins, H. A. Feldman, R. G. Zoble, D. Newman, S. G. Spitzer, H.-C. Diener, and G. W. Albers Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials Stroke, March 1, 2007; 38(3): 874 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat, A. Capucci, G. Y.H. Lip, S. B. Olsson, M. H. Prins, F. H. Nieman, J. Lopez-Sendon, P. E. Vardas, E. Aliot, M. Santini, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation Eur. Heart J., December 2, 2006; 27(24): 3018 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist Stroke prophylaxis in atrial fibrillation: who gets it and who does not?: Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study) Eur. Heart J., August 2, 2006; 27(16): 1954 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Garcia, S. Regan, M. Crowther, R. A. Hughes, and E. M. Hylek Warfarin Maintenance Dosing Patterns in Clinical Practice: Implications for Safer Anticoagulation in the Elderly Population Chest, June 1, 2005; 127(6): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-y. Hsu Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization N. Engl. J. Med., September 23, 2004; 351(13): 1296 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bode Recent trials in atrial fibrillation: lessons learned beyond rate and rhythm Eur. Heart J. Suppl., April 1, 2004; 6(suppl_B): B15 - B19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Hylek, A. S. Go, Y. Chang, N. G. Jensvold, L. E. Henault, J. V. Selby, and D. E. Singer Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation N. Engl. J. Med., September 11, 2003; 349(11): 1019 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Waldo Stroke Prevention in Atrial Fibrillation JAMA, August 27, 2003; 290(8): 1093 - 1095. [Full Text] [PDF]
|
|
|
|
 |
|
 C. van Walraven, R. G. Hart, G. A. Wells, P. Petersen, P. J. Koudstaal, A. L. Gullov, B. S. P. Hellemons, B. G. Koefed, and A. Laupacis A Clinical Prediction Rule to Identify Patients With Atrial Fibrillation and a Low Risk for Stroke While Taking Aspirin Arch Intern Med, April 28, 2003; 163(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Man-Son-Hing and A. Laupacis Balancing the Risks of Stroke and Upper Gastrointestinal Tract Bleeding in Older Patients With Atrial Fibrillation Arch Intern Med, March 11, 2002; 162(5): 541 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McCormick, J. H. Gurwitz, R. J. Goldberg, R. Becker, J. P. Tate, A. Elwell, and M. J. Radford Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting Arch Intern Med, November 12, 2001; 161(20): 2458 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Majeed, K Moser, and K Carroll Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database Heart, September 1, 2001; 86(3): 284 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart and J. L. Halperin Atrial Fibrillation and Stroke : Concepts and Controversies Stroke, March 1, 2001; 32(3): 803 - 808. [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Hart Anticoagulation therapy for patients with atrial fibrillation Can. Med. Assoc. J., October 1, 2000; 163(8): 956 - 957. [Full Text] [PDF]
|
|
|
|
|
|
A. Villa, A. Bacchetta, E. Omboni, and B. F. Gage Underuse of Antithrombotic Therapy in Stroke Patients With Chronic Atrial Fibrillation Response Stroke, September 1, 2000; 31(9): 2266 - 2278. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Go, E. M. Hylek, K. A. Phillips, L. H. Borowsky, L. E. Henault, Y. Chang, J. V. Selby, and D. E. Singer Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation : The Anticoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study Circulation, July 4, 2000; 102(1): 11 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Real-World Warfarin Use and Atrial Fibrillation Journal Watch Cardiology, February 11, 2000; 2000(211): 4 - 4. [Full Text]
|
|
Article
